Navigation Links
Panel suggests selling allergy drugs OTC

An advisory committee to the U.S. Food and Drug Administration recommended that three popular allergy drugs are safe enough to be used without a prescription. The FDA does not have to follow the advice of its advisory committee, though it usually does. There is no deadline for making a decision. //

"Drugs are prescription for a reason. They have the ability to do both good and harm. Claritin, Allegra and Zyrtec have almost no side effects and are equally effective as the antihistamines that are available over the counter today." said Robert Seidman, WellPoint's chief pharmacy officer.

Anti-allergy medications have been linked to side effects in some users that include reduced alertness, nausea and headache. By prescription, the drugs cost about $80 per month versus $10 to $15 in the 17 nations where the drugs are over-the-counter. The drug makers oppose a switch, which would cost them money.

Usually, drug companies support making a drug over-the-counter only when their patent is about to run out, because doing so at that time extends the period during which makers of generic drugs are prohibited from selling lower-priced versions of the drug.

Claritin's patent is due to expire in 2002, but the company is waging a multi-million-dollar campaign to get it extended. Aventis Pharmaceuticals, which manufactures Allegra, also expressed its disappointment. According to WellPoint, sales of Allegra, Claritin and Zyrtec exceeded $5 billion last year.
'"/>




Page: 1

Related medicine news :

1. Anti-Quota Stir: Resident Docs Demand Experts Panel
2. Circumcision Studies to Continue Says Health Panel
3. Panel to Help Combat HIV/AIDS In Asia-Pacific Region
4. Breast Cancer Review Panel Adds Two Experts
5. Shingles Vaccine For Older People - Panel Recommendation
6. Complaints Against US Federal lab Over-ruled by Panel
7. E.U. Panel Backs Novartis Mock-up Pandemic Flu Vaccine
8. Generic Biologics – U.S Panel Hearing Draws Mixed Response
9. Expert Panel Sets Limits on Pesticide Residues in Soft Drinks
10. Mercks Pain Reliever Arcoxia Rejected by US Federal Advisory Panel
11. National Pharmaceutical Policy Referred to Ministerial Panel
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/12/2017)... , ... October 12, 2017 , ... ... a leader in post-acute health care, have expanded their existing home health joint ... Health. , AccentCare has been operating a joint venture home health company with ...
(Date:10/12/2017)... ANGELES (PRWEB) , ... October 12, 2017 , ... ... Parsa Mohebi Hair Restoration, has recently contributed a medical article to the newly ... on cosmetictown.com. Dr. Mohebi’s article spotlights the hair transplant procedure known as ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... Leading pediatric ... peers in Washington, D.C., for the 49th Congress of the International Society of ... Vice President of the Center for Cancer and Blood Disorders at Children’s ...
(Date:10/12/2017)... GRAND RAPIDS, Mich. (PRWEB) , ... October 12, ... ... OnSite Wellness, has been named one of Michigan’s 2017 Best and Brightest in ... Best and Brightest in Wellness® awards program on Friday, Oct. 20 from 7:30 ...
(Date:10/12/2017)... ... October 12, 2017 , ... In the United ... year. In some states—like New York, New Jersey, Massachusetts, Texas, Virginia, Connecticut, and ... havens have extremely low property-tax rates, which contributes to the relatively lower cost ...
Breaking Medicine News(10 mins):
(Date:9/28/2017)... , Sept. 28, 2017 Cohen Veterans ... advance the use of wearable and home sensors for ... disorders. Early Signal Foundation, a nonprofit organization focused on ... will provide an affordable analytical system to record and ... ...
(Date:9/25/2017)... Sept. 25, 2017  EpiVax, Inc., a leader ... and immune-engineering today announced the launch of EpiVax ... of personalized therapeutic cancer vaccines. EpiVax has provided ... access to enabling technologies to the new precision ... lead EpiVax Oncology as Chief Executive Officer. Gad ...
(Date:9/19/2017)... Inc., a venture-backed medical device company developing a non-invasive, robotically assisted, platform therapy that uses ... today:   ... Jim ... Tom Tefft ... Veteran medical device executive Josh Stopek , PhD, who has led R&D and business ...
Breaking Medicine Technology: